These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19696792)

  • 1. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
    Cha PC; Mushiroda T; Zembutsu H; Harada H; Shinoda N; Kawamoto S; Shimoyama R; Nishidate T; Furuhata T; Sasaki K; Hirata K; Nakamura Y
    J Hum Genet; 2009 Oct; 54(10):572-80. PubMed ID: 19696792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
    Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
    Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
    de Jong FA; Marsh S; Mathijssen RH; King C; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2004 Sep; 10(17):5889-94. PubMed ID: 15355921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
    Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].
    Sugimoto Y
    Seikagaku; 2005 Sep; 77(9):1196-200. PubMed ID: 16241009
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
    Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
    Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
    van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
    Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
    Takahashi H; Sai K; Saito Y; Kaniwa N; Matsumura Y; Hamaguchi T; Shimada Y; Ohtsu A; Yoshino T; Doi T; Okuda H; Ichinohe R; Takahashi A; Doi A; Odaka Y; Okuyama M; Saijo N; Sawada J; Sakamoto H; Yoshida T
    PLoS One; 2014; 9(8):e105160. PubMed ID: 25127363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
    Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
    Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
    Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
    Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
    Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.